Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 15/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909237 | 0.89 | PGR (0.58) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL4176564 | 0.89 | PGR (0.58) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL4163167 | 0.84 | PGR (0.73) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL291078 | 0.83 | PGR (1.00) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL292001 | 0.83 | PGR (0.86) | PGRNR3C1NR3C2 | |
| SCHEMBL4161922 | 0.82 | PGR (0.60) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL13909230 | 0.82 | PGR (0.60) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL20418656 | 0.81 | NR3C1 (0.62) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL291183 | 0.79 | PGR (1.00) | PGRNR3C1NR3C2 | |
| SCHEMBL6583293 | 0.78 | PGR (0.89) | PGRNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | PGR 5/4885NR3C1 60/4885NR3C2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.